Compare Estee Lauder Companies Inc (EL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Estée Lauder (EL) trades at $101.59, up 1.55% with strong technical momentum and bullish moving average signals. The company shows improving operational trends with three consecutive quarterly earnings beats, though 2025 results reflect a net loss of $1.13B amid revenue contraction. Recent strategic partnerships in AI marketing and leadership appointments signal transformation efforts, while analyst consensus remains positive with a $103 price target.

The stock presents a turnaround opportunity with margin recovery potential and digital innovation initiatives, but faces execution risks from competitive pressures and debt levels. Current valuation multiples appear elevated relative to profitability metrics, requiring careful monitoring of Q3 2026 earnings delivery for confirmation of sustained improvement.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.